Parenteral Drug (India) financials and balance sheet

BSE: 524689Pharmaceuticals & Biotechnology

Trading suspended since 3 Feb 2025

Last traded ₹2.90 on 21 Aug 2023

10 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Parenteral Drug (India) annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
A loss in 9 of the 9 years with results on record

Operating and net margin, per cent

  • Operating margin
  • Net margin

The years either side of a change of basis do not compare. From the year to Mar 2018, the company's revenue for that year, ₹33 Cr, differs from its quarters added, ₹36 Cr.

Results for the year to Mar 2022

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue8.5
  2. Materials and goods−5.5
  3. Employee costs−15
  4. Other expenses−3.3
  5. Operating profit−15
  6. Depreciation−40
  7. Other income+0.1
  8. One-off items+52
  9. Finance costs−106
  10. Profit before tax−109
  11. Tax+33
  12. Net profit−76

What the company owns

  • Plant, investments and other assets₹473 Cr
  • Cash and bank₹9 Cr
  • Inventory₹1 Cr

What pays for it: net worth and liabilities

  • Owed to suppliers₹1,076 Cr
  • Borrowings₹116 Cr

Profit and loss

Standalone, ₹ crore, years to March. No results on record for the year to Mar 2016.Parenteral Drug (India) quarterly results

₹ croreMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Filed 29 JunMar 2019Filed 13 JunMar 2020Filed 1 AugMar 2021Filed 8 JulMar 2022Filed 16 Jun
Revenue from operations187187177–55333232128
209204163–874950472424
Materials and goods bought11710679–2676665
Employee costs171918–161720191515
Other expenses758066–4525232143
Operating profit before depreciation−22−1713–−32−16−18−15−12−15
Operating margin−11.8%−8.9%7.6%–−58.7%−48.0%−55.1%−46.1%−96.7%−176.7%
Materials, % of revenue62.7%56.5%44.8%–47.6%20.5%20.2%19.8%46.5%64.3%
Employee costs, % of revenue9.3%9.9%10.4%–29.3%50.6%62.3%60.3%119.3%174.0%
Other expenses, % of revenue39.9%42.6%37.2%–81.8%76.9%72.7%66.0%30.9%38.3%
Depreciation and amortisation171824–191969171740
Operating profit after depreciation−39−34−10–−51−34−87−32−29−55
Other income–––––11000
Finance costs425459–748696110125106
Profit before one-off items and tax−82−89−70–−125−119−181−142−154−161
One-off items–340–0000052
Profit before tax−82−55−70–−125−119−181−142−154−109
34−16–−12−23−33−28−33−33
Net profit−85−59−54–−113−96−148−114−122−76
Other comprehensive income–––––00000
Total comprehensive income–––––−96−148−114−122−76
Net margin−45.5%−31.4%−30.6%–−207.4%−291.4%−461.8%−357.9%−1,000.3%−898.8%
Earlier years, Mar 2008 to Mar 2012
₹ croreMar 2008Mar 2009Mar 2010Mar 2011Mar 2012
Revenue from operations208244342397223
169202284352214
Materials and goods bought84108169198–
Employee costs9101216–
Other expenses7685102139–
Operating profit before depreciation394258459
Operating margin18.9%17.3%17.0%11.3%4.0%
Materials, % of revenue40.5%44.1%49.5%49.7%–
Employee costs, % of revenue4.2%4.0%3.6%3.9%–
Other expenses, % of revenue36.4%34.6%29.9%35.1%–
Depreciation and amortisation466813
Operating profit after depreciation36375236−4
Other income2––––
Finance costs1214152339
Profit before tax25233714−43
Tax331055
Net profit2320279−48
Net margin10.9%8.2%7.8%2.2%−21.5%
Standalone, ₹ crore, years to March.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2018Filed 29 JunMar 2019Filed 13 JunMar 2020Filed 1 AugMar 2021Filed 8 JulMar 2022Filed 16 Jun
−108−447−562−683−824
Share capital3030303030
Reserves−138−477−591−713−854
468109106106116
5318781,0061,1441,201
341109106106106
Total assets764539550567483
700473484499416
6567676766
Net debt468108106106108
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2013, Mar 2014, Mar 2015 and Mar 2017, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Filed 8 JulMar 2022Filed 16 Jun
1250
13714
Inventories01
Payables02
Other working capital13711
Capital spending00
Free cash flow1250
065
−125−64
Dividends paid00
Shares bought back00
Shares issued00
Net change in cash00
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2013, Mar 2014, Mar 2015, Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.Parenteral Drug (India) dividend history

₹ per shareMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Filed 29 JunMar 2019Filed 13 JunMar 2020Filed 1 AugMar 2021Filed 8 JulMar 2022Filed 16 Jun
Earnings per share−₹32.94–––−₹38.00−₹32.23−₹49.61−₹38.26−₹40.82−₹25.61
Diluted earnings per share−₹32.94–––−₹38.00−₹32.23−₹49.61−₹38.26−₹40.82−₹25.61
Book value per share–––––−₹36.15−₹150.00−₹188.36−₹229.14−₹276.48
Shareholder yield––––––––0.0%0.0%
Market cap at the year end (₹ crore)22889––8146258911

Ratios

Standalone, years to March.

RatioMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Filed 29 JunMar 2019Filed 13 JunMar 2020Filed 1 AugMar 2021Filed 8 JulMar 2022Filed 16 Jun
Revenue growth−15.9%−0.2%−5.5%–––−2.9%−0.5%−61.8%−30.2%
–––––89.2%53.3%22.6%19.6%10.1%
––––––−35.9 pts−30.7 pts−3.1 pts−9.4 pts
From the net margin––––––52.1 pts−12.0 pts40.6 pts−2.0 pts
From asset turnover––––––19.7 pts7.9 pts−39.7 pts−4.5 pts
From borrowing––––––−107.6 pts−26.6 pts−4.0 pts−2.9 pts
Return on capital employed–––––−9.5%––––
Receivable days–––––6320000
Inventory days–––––672247210369
Payable days–––––73367145850371,855
Cash conversion cycle, days–––––−34−446−385−401−71,786
Working capital days–––––−3,759−9,247−10,753−32,288−48,680
Asset turnover–––––0.040.050.060.020.02
Assets per rupee of net worth–––––−7.09−2.35−1.08−0.90−0.70
Sales per rupee of plant–––––0.050.090.090.040.04
Capital spending to depreciation––––––––0.000.00
Plant being built, % of plant in use–––––––0.0%0.0%0.0%
Interest cover is left blank for the years to Mar 2013, Mar 2014, Mar 2015, Mar 2017, Mar 2018, Mar 2019, Mar 2020, Mar 2021 and Mar 2022: operating profit after depreciation is a loss, and a loss covers no interest bill. Debt to equity is left blank for the years to Mar 2018, Mar 2019, Mar 2020, Mar 2021 and Mar 2022: net worth is below zero, so there is no shareholders' money to set the borrowings against. Revenue growth is left blank for the year to Mar 2018: between the two periods the company restated its earlier figures, so the two are on different bases and the change is not worked out. Return on capital employed is left blank for the years to Mar 2019, Mar 2020, Mar 2021 and Mar 2022: net worth and borrowings together come to nought or less, so there is no money employed to set the operating profit against. No balance sheet is on record for the years to Mar 2013, Mar 2014, Mar 2015 and Mar 2017, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2022.

Return on assets, latest year
−14.6%
Measure10 years5 years3 years
Revenue growth, yearly rate−27.9%−31.1%−35.7%
Return on equity, average–39.0%17.4%
Operating margin, average−55.0%−84.5%−106.5%
Net margin, average−369.5%−602.0%−752.3%
Asset turnover, average–0.040.03
Cash conversion cycle, days, average–−14,610−24,191

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2022.

₹ croreLatest year
Cash from operations−0.5
Cash from investing64.7
Cash from financing−64.3
Capital spending0.0
Dividends paid0.0
Shares bought back0.0
Shares issued for cash0.0
Borrowings raised35.1
Borrowings repaid0.0